Bristol Cash And Short Term Investments vs Total Current Liabilities Analysis

BMY Stock

USD 41.24 0.30 0.72%

Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Cash And Short Term Investments and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Cash And Short Term Investments vs Total Current Liabilities

Cash And Short Term Investments vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Cash And Short Term Investments account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.

The correlation between Bristol Myers' Cash And Short Term Investments and Total Current Liabilities is 0.75. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Cash And Short Term Investments and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Bristol Myers Squibb are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Cash And Short Term Investments i.e., Bristol Myers' Cash And Short Term Investments and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.75

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Bristol Myers Squibb balance sheet. This account contains Bristol Myers investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Bristol Myers Squibb fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Total Current Liabilities

Total Current Liabilities is an item on Bristol Myers balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bristol Myers Squibb are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

At this time, Bristol Myers' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	36.4B	36.0B	34.3B	36.0B
Total Revenue	46.4B	46.2B	45.0B	47.3B

Gross Profit Total Revenue

Bristol Myers fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock Total Equity
Total Assets		0.98	0.81	0.93	0.89	0.78	0.98	-0.07	0.9	0.99	0.52	0.83	0.76	0.97	0.45	0.99	0.82	-0.16	0.88	0.99	0.7	0.94	0.85	0.96	0.6	0.88
Short Long Term Debt Total	0.98		0.78	0.92	0.84	0.79	1.0	-0.16	0.94	0.97	0.38	0.88	0.82	0.98	0.52	0.99	0.76	-0.24	0.89	0.99	0.76	0.95	0.89	0.95	0.57	0.91
Other Current Liab	0.81	0.78		0.95	0.55	0.69	0.81	-0.1	0.63	0.77	0.64	0.55	0.77	0.81	0.39	0.76	0.52	0.1	0.6	0.83	0.77	0.87	0.67	0.65	0.62	0.73
Total Current Liabilities	0.93	0.92	0.95		0.7	0.8	0.93	-0.07	0.81	0.89	0.52	0.75	0.88	0.95	0.41	0.9	0.66	-0.04	0.73	0.94	0.87	0.97	0.84	0.8	0.66	0.85
Total Stockholder Equity	0.89	0.84	0.55	0.7		0.75	0.84	0.13	0.79	0.91	0.41	0.73	0.5	0.82	0.44	0.88	0.9	-0.14	0.82	0.85	0.43	0.76	0.73	0.93	0.62	0.81
Property Plant And Equipment Net	0.78	0.79	0.69	0.8	0.75		0.79	0.28	0.73	0.76	0.19	0.7	0.77	0.84	0.41	0.78	0.64	-0.13	0.53	0.8	0.75	0.79	0.78	0.7	0.85	0.85
Net Debt	0.98	1.0	0.81	0.93	0.84	0.79		-0.17	0.9	0.98	0.42	0.83	0.82	0.98	0.52	0.99	0.77	-0.21	0.89	0.99	0.76	0.93	0.89	0.95	0.56	0.91
Retained Earnings	-0.07	-0.16	-0.1	-0.07	0.13	0.28	-0.17		-0.12	-0.07	-0.11	-0.07	-0.11	-0.03	-0.62	-0.12	0.17	0.35	-0.45	-0.11	-0.06	-0.05	-0.16	-0.13	0.44	-0.14
Cash	0.9	0.94	0.63	0.81	0.79	0.73	0.9	-0.12		0.87	0.21	0.98	0.78	0.9	0.48	0.92	0.66	-0.32	0.83	0.91	0.69	0.91	0.85	0.87	0.57	0.84
Non Current Assets Total	0.99	0.97	0.77	0.89	0.91	0.76	0.98	-0.07	0.87		0.53	0.8	0.71	0.95	0.46	0.99	0.84	-0.19	0.89	0.98	0.65	0.91	0.83	0.98	0.57	0.86
Non Currrent Assets Other	0.52	0.38	0.64	0.52	0.41	0.19	0.42	-0.11	0.21	0.53		0.12	0.16	0.38	0.18	0.45	0.49	0.12	0.44	0.48	0.18	0.45	0.18	0.45	0.21	0.35
Cash And Short Term Investments	0.83	0.88	0.55	0.75	0.73	0.7	0.83	-0.07	0.98	0.8	0.12		0.76	0.84	0.41	0.85	0.6	-0.37	0.74	0.84	0.67	0.87	0.8	0.8	0.58	0.78
Net Receivables	0.76	0.82	0.77	0.88	0.5	0.77	0.82	-0.11	0.78	0.71	0.16	0.76		0.88	0.35	0.76	0.48	-0.29	0.58	0.8	0.97	0.86	0.87	0.62	0.53	0.8
Good Will	0.97	0.98	0.81	0.95	0.82	0.84	0.98	-0.03	0.9	0.95	0.38	0.84	0.88		0.4	0.97	0.78	-0.19	0.81	0.98	0.83	0.95	0.9	0.9	0.63	0.89
Common Stock Shares Outstanding	0.45	0.52	0.39	0.41	0.44	0.41	0.52	-0.62	0.48	0.46	0.18	0.41	0.35	0.4		0.5	0.2	-0.34	0.69	0.48	0.29	0.4	0.52	0.5	0.27	0.64
Non Current Liabilities Total	0.99	0.99	0.76	0.9	0.88	0.78	0.99	-0.12	0.92	0.99	0.45	0.85	0.76	0.97	0.5		0.8	-0.22	0.9	0.99	0.69	0.93	0.86	0.97	0.58	0.88
Inventory	0.82	0.76	0.52	0.66	0.9	0.64	0.77	0.17	0.66	0.84	0.49	0.6	0.48	0.78	0.2	0.8		-0.07	0.72	0.78	0.45	0.69	0.65	0.86	0.52	0.75
Other Current Assets	-0.16	-0.24	0.1	-0.04	-0.14	-0.13	-0.21	0.35	-0.32	-0.19	0.12	-0.37	-0.29	-0.19	-0.34	-0.22	-0.07		-0.33	-0.18	-0.19	-0.07	-0.32	-0.24	0.15	-0.26
Other Stockholder Equity	0.88	0.89	0.6	0.73	0.82	0.53	0.89	-0.45	0.83	0.89	0.44	0.74	0.58	0.81	0.69	0.9	0.72	-0.33		0.87	0.49	0.77	0.78	0.94	0.3	0.81
Total Liab	0.99	0.99	0.83	0.94	0.85	0.8	0.99	-0.11	0.91	0.98	0.48	0.84	0.8	0.98	0.48	0.99	0.78	-0.18	0.87		0.75	0.96	0.87	0.95	0.61	0.89
Property Plant And Equipment Gross	0.7	0.76	0.77	0.87	0.43	0.75	0.76	-0.06	0.69	0.65	0.18	0.67	0.97	0.83	0.29	0.69	0.45	-0.19	0.49	0.75		0.82	0.83	0.55	0.56	0.75
Total Current Assets	0.94	0.95	0.87	0.97	0.76	0.79	0.93	-0.05	0.91	0.91	0.45	0.87	0.86	0.95	0.4	0.93	0.69	-0.07	0.77	0.96	0.82		0.85	0.84	0.68	0.86
Short Term Debt	0.85	0.89	0.67	0.84	0.73	0.78	0.89	-0.16	0.85	0.83	0.18	0.8	0.87	0.9	0.52	0.86	0.65	-0.32	0.78	0.87	0.83	0.85		0.82	0.53	0.84
Intangible Assets	0.96	0.95	0.65	0.8	0.93	0.7	0.95	-0.13	0.87	0.98	0.45	0.8	0.62	0.9	0.5	0.97	0.86	-0.24	0.94	0.95	0.55	0.84	0.82		0.5	0.83
Accounts Payable	0.6	0.57	0.62	0.66	0.62	0.85	0.56	0.44	0.57	0.57	0.21	0.58	0.53	0.63	0.27	0.58	0.52	0.15	0.3	0.61	0.56	0.68	0.53	0.5		0.64
Common Stock Total Equity	0.88	0.91	0.73	0.85	0.81	0.85	0.91	-0.14	0.84	0.86	0.35	0.78	0.8	0.89	0.64	0.88	0.75	-0.26	0.81	0.89	0.75	0.86	0.84	0.83	0.64

Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Short Long Term Debt Total	47.5B	51.7B	45.6B	40.7B	41.5B	43.5B
Other Current Liab	7.9B	10.2B	10.1B	13.1B	11.5B	12.1B
Total Current Liabilities	18.3B	19.1B	21.9B	21.9B	22.3B	23.4B
Total Stockholder Equity	51.6B	37.8B	35.9B	31.1B	29.4B	15.0B
Property Plant And Equipment Net	6.3B	6.7B	7.0B	7.5B	8.0B	5.2B
Net Debt	35.2B	37.1B	31.6B	31.6B	30B	31.5B
Retained Earnings	34.5B	21.3B	23.8B	25.5B	28.8B	22.0B
Cash	12.3B	14.5B	14.0B	9.1B	11.5B	12.0B
Non Current Assets Total	100.6B	88.3B	76.1B	69.5B	63.4B	66.6B
Non Currrent Assets Other	6.6B	2.1B	1.7B	1.0B	1.9B	2.0B
Cash And Short Term Investments	12.3B	14.5B	14.0B	9.1B	12.3B	12.9B
Net Receivables	7.7B	8.5B	12.5B	13.9B	15.3B	16.0B
Good Will	22.5B	20.5B	20.5B	21.1B	21.2B	22.2B
Common Stock Shares Outstanding	1.7B	2.3B	2.2B	2.1B	2.1B	1.6B
Liabilities And Stockholders Equity	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Non Current Liabilities Total	59.9B	61.5B	51.4B	43.8B	43.4B	45.6B
Inventory	4.3B	2.1B	2.1B	2.3B	2.7B	1.9B
Other Current Assets	2.0B	1.4B	1.3B	1.6B	1.5B	1.8B
Other Stockholder Equity	18.4B	18.1B	13.1B	6.5B	1.9B	2.0B
Total Liab	78.2B	80.6B	73.3B	65.7B	65.7B	69.0B
Property Plant And Equipment Gross	6.3B	5.9B	11.0B	11.6B	12.8B	13.5B
Total Current Assets	29.4B	30.2B	33.3B	27.3B	31.8B	33.4B
Accumulated Other Comprehensive Income	(1.5B)	(1.8B)	(1.3B)	(1.3B)	(1.5B)	(1.6B)
Short Term Debt	3.5B	2.5B	5.1B	4.4B	3.3B	3.4B
Intangible Assets	64.0B	53.2B	42.8B	36.4B	27.5B	28.9B
Accounts Payable	2.4B	2.7B	2.9B	3.0B	3.3B	1.9B
Short Term Investments	3.0B	1.3B	3.2B	130M	816M	775.2M
Other Liab	15.9B	12.3B	11.0B	7.4B	8.5B	4.9B
Other Assets	4.8B	7.3B	3.3B	2.9B	3.3B	3.3B
Long Term Debt	43.4B	48.3B	39.6B	35.1B	36.7B	38.5B
Treasury Stock	(25.4B)	(26.2B)	(31.3B)	(38.6B)	(43.8B)	(41.6B)
Property Plant Equipment	6.3B	5.9B	6.0B	6.3B	7.2B	5.8B
Current Deferred Revenue	4.5B	3.6B	3.7B	1.3B	4.2B	4.4B
Net Tangible Assets	(34.9B)	(36.0B)	(28.2B)	(25.9B)	(23.4B)	(22.2B)
Noncontrolling Interest In Consolidated Entity	96M	100M	60M	57M	55M	74.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
GM	General Motors
BAC	Bank of America

When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:

How To Invest In Bristol

Details

Is Bristol Stock a good investment?

Details

What is Bristol Myers' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum

Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.09)

Dividend Share

2.34

Earnings Share

(3.10)

Revenue Per Share

22.212

Quarterly Revenue Growth

0.047

The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Cash And Short Term Investments vs Total Current Liabilities Analysis

Cash And Short Term Investments vs Total Current Liabilities

Cash And Short Term Investments vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Total Current Liabilities

Bristol Myers fundamental ratios Correlations

Bristol Myers Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bristol Myers fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Bristol Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.62	Retained Earnings
Other Stockholder Equity	- 0.45	Retained Earnings
Other Current Assets	- 0.37	Cash And Short Term Investments
Other Current Assets	- 0.34	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.33	Other Current Assets
Short Term Debt	- 0.32	Other Current Assets